Single-cell RNA Sequencing Unveils Tumor Heterogeneity and Immune Microenvironment Between Subungual and Plantar Melanoma

Overview

Journal Sci Rep

Specialty Science

Date 2024 Mar 26

PMID 38528036

Authors

Panpan Wang

Yangyang Ma

Yige Zhao

Yong Li

Chenyu Tang

Shiwen Wang

Sha Jin

Jiaqi Wang

Mengyan Zhu

Bo Xie

Ping Wang

Affiliations

Soon will be listed here.

Abstract

Acral melanoma (AM) is a subtype of melanoma with high prevalence in East Asians. AM is characterized by greater aggressiveness and lower survival rates. However, there are still fewer studies on immune mechanisms of AM especially subungual melanoma (SM) versus non-subungual melanoma (NSM). In order to explore tumor heterogeneity and immune microenvironment in different subtypes of AM, we applied single-cell RNA sequencing to 24,789 single cells isolated from the SM and plantar melanoma (PM) patients. Aspects of tumor heterogeneity, melanocytes from PM and SM had significant differences in gene expression, CNV and pathways in which tumor-associated such as NF-kb and Wnt were involved. Regarding the immune microenvironment, PM contained more fibroblasts and T/NK cells. The EPHA3-EFNA1 axis was expressed only in cancer-associated fibroblast (CAF) and melanocytes of PM, and the TIGIT-NECTIN2 axis was expressed in both AM subtypes of T/NK cells and melanocytes. Altogether, our study helps to elucidate the tumor heterogeneity in AM subpopulations and provides potential therapeutic targets for clinical research.

References

Miyazaki K, Inokuchi M, Takagi Y, Kato K, Kojima K, Sugihara K . EphA4 is a prognostic factor in gastric cancer. BMC Clin Pathol. 2013; 13(1):19. PMC: 3720259. DOI: 10.1186/1472-6890-13-19. View

Lozano E, Dominguez-Villar M, Kuchroo V, Hafler D . The TIGIT/CD226 axis regulates human T cell function. J Immunol. 2012; 188(8):3869-75. PMC: 3324669. DOI: 10.4049/jimmunol.1103627. View

Guo J, Xiao Y, Iyer R, Lu X, Lake M, Ladror U . Empowering therapeutic antibodies with IFN-α for cancer immunotherapy. PLoS One. 2019; 14(8):e0219829. PMC: 6687177. DOI: 10.1371/journal.pone.0219829. View

Talia M, Cirillo F, Spinelli A, Zicarelli A, Scordamaglia D, Muglia L . The Ephrin tyrosine kinase a3 (EphA3) is a novel mediator of RAGE-prompted motility of breast cancer cells. J Exp Clin Cancer Res. 2023; 42(1):164. PMC: 10337103. DOI: 10.1186/s13046-023-02747-5. View

Newell F, Wilmott J, Johansson P, Nones K, Addala V, Mukhopadhyay P . Whole-genome sequencing of acral melanoma reveals genomic complexity and diversity. Nat Commun. 2020; 11(1):5259. PMC: 7567804. DOI: 10.1038/s41467-020-18988-3. View

Van Hove L, Hoste E . Activation of Fibroblasts in Skin Cancer. J Invest Dermatol. 2021; 142(4):1026-1031. DOI: 10.1016/j.jid.2021.09.010. View

Xu K, Wang R, Xie H, Hu L, Wang C, Xu J . Single-cell RNA sequencing reveals cell heterogeneity and transcriptome profile of breast cancer lymph node metastasis. Oncogenesis. 2021; 10(10):66. PMC: 8492772. DOI: 10.1038/s41389-021-00355-6. View

Si L, Kong Y, Xu X, Flaherty K, Sheng X, Cui C . Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohort. Eur J Cancer. 2011; 48(1):94-100. DOI: 10.1016/j.ejca.2011.06.056. View

Shi Z, Zhang Y, Shang L, Hao J, Zhang T, Wang B . Genomic profiling of rectal adenoma and carcinoma by array-based comparative genomic hybridization. BMC Med Genomics. 2012; 5:52. PMC: 3533962. DOI: 10.1186/1755-8794-5-52. View

10.

Jagirdar K, Portuallo M, Wei M, Wilhide M, Bravo Narula J, Robertson B . ERK hyperactivation serves as a unified mechanism of escape in intrinsic and acquired CDK4/6 inhibitor resistance in acral lentiginous melanoma. Oncogene. 2023; 43(6):395-405. PMC: 10837073. DOI: 10.1038/s41388-023-02900-6. View

11.

Worboys J, Vowell K, Hare R, Ambrose A, Bertuzzi M, Conner M . TIGIT can inhibit T cell activation via ligation-induced nanoclusters, independent of CD226 co-stimulation. Nat Commun. 2023; 14(1):5016. PMC: 10439114. DOI: 10.1038/s41467-023-40755-3. View

12.

Toma M, Erdmann K, Diezel M, Meinhardt M, Zastrow S, Fuessel S . Lack of ephrin receptor A1 is a favorable independent prognostic factor in clear cell renal cell carcinoma. PLoS One. 2014; 9(7):e102262. PMC: 4099180. DOI: 10.1371/journal.pone.0102262. View

13.

Schoepp M, Strose A, Haier J . Dysregulation of miRNA Expression in Cancer Associated Fibroblasts (CAFs) and Its Consequences on the Tumor Microenvironment. Cancers (Basel). 2017; 9(6). PMC: 5483873. DOI: 10.3390/cancers9060054. View

14.

Sheppard K, McArthur G . The cell-cycle regulator CDK4: an emerging therapeutic target in melanoma. Clin Cancer Res. 2013; 19(19):5320-8. DOI: 10.1158/1078-0432.CCR-13-0259. View

15.

Zhang J, Zhou X, Huang D, Luan C, Gu H, Ju M . Development of an Immune-Related Gene Signature for Prognosis in Melanoma. Front Oncol. 2021; 10:602555. PMC: 7874014. DOI: 10.3389/fonc.2020.602555. View

16.

Miao H, Gale N, Guo H, Qian J, Petty A, Kaspar J . EphA2 promotes infiltrative invasion of glioma stem cells in vivo through cross-talk with Akt and regulates stem cell properties. Oncogene. 2014; 34(5):558-67. PMC: 4119862. DOI: 10.1038/onc.2013.590. View

17.

Rishiq A, Bsoul R, Pick O, Mandelboim O . Studying TIGIT activity against tumors through the generation of knockout mice. Oncoimmunology. 2023; 12(1):2217735. PMC: 10228407. DOI: 10.1080/2162402X.2023.2217735. View

18.

Namikawa K, Yoshino K, Yoshikawa S, Uchi H, Goto K, Nakamura Y . Anti-PD1 checkpoint inhibitor therapy in acral melanoma: a multicenter study of 193 Japanese patients. Ann Oncol. 2020; 31(9):1198-1206. DOI: 10.1016/j.annonc.2020.05.031. View

19.

Du X, De Almeida P, Manieri N, de Almeida Nagata D, Wu T, Bowles K . CD226 regulates natural killer cell antitumor responses via phosphorylation-mediated inactivation of transcription factor FOXO1. Proc Natl Acad Sci U S A. 2018; 115(50):E11731-E11740. PMC: 6294892. DOI: 10.1073/pnas.1814052115. View

20.

Angell H, Galon J . From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer. Curr Opin Immunol. 2013; 25(2):261-7. DOI: 10.1016/j.coi.2013.03.004. View